440 related articles for article (PubMed ID: 29633300)
1. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
Trinidad C; Nelson KC; Glitza Oliva IC; Torres-Cabala CA; Nagarajan P; Tetzlaff MT; Ivan D; Hwu WJ; Prieto VG; Curry JL; Aung PP
J Cutan Pathol; 2018 Jul; 45(7):504-507. PubMed ID: 29633300
[TBL] [Abstract][Full Text] [Related]
2. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
3. Histopathological aspects of cutaneous erythematous-papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma.
Perret RE; Josselin N; Knol AC; Khammari A; Cassecuel J; Peuvrel L; Dreno B;
Int J Dermatol; 2017 May; 56(5):527-533. PubMed ID: 28188628
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
5. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Hwang SJE; Fernández-Peñas P
Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
8. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
Curry JL; Tetzlaff MT; Nagarajan P; Drucker C; Diab A; Hymes SR; Duvic M; Hwu WJ; Wargo JA; Torres-Cabala CA; Rapini RP; Prieto VG
J Cutan Pathol; 2017 Feb; 44(2):158-176. PubMed ID: 27859479
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
[TBL] [Abstract][Full Text] [Related]
10. Granulomatous dermatitis associated with ipilimumab therapy (ipilimumab associated granulomatous dermatitis).
Kubicki SL; Welborn ME; Garg N; Aung PP; Patel AB
J Cutan Pathol; 2018 Aug; 45(8):636-638. PubMed ID: 29704281
[No Abstract] [Full Text] [Related]
11. Lichenoid Dermatologic Toxicity From Immune Checkpoint Blockade Therapy: A Detailed Examination of the Clinicopathologic Features.
Tetzlaff MT; Nagarajan P; Chon S; Huen A; Diab A; Omar P; Aung PP; Torres-Cabala CA; Mays SR; Prieto VG; Curry JL
Am J Dermatopathol; 2017 Feb; 39(2):121-129. PubMed ID: 28134729
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.
Jour G; Glitza IC; Ellis RM; Torres-Cabala CA; Tetzlaff MT; Li JY; Nagarajan P; Huen A; Aung PP; Ivan D; Drucker CR; Prieto VG; Rapini RP; Patel A; Curry JL
J Cutan Pathol; 2016 Aug; 43(8):688-96. PubMed ID: 27086658
[TBL] [Abstract][Full Text] [Related]
13. [Acceptability and effectiveness of immunotherapy in patients with melanoma].
Valnet-Rabier MB; Marcucci C; Limat S; Davani S; Aubin F; Nerich V
Therapie; 2019 Jun; 74(3):355-367. PubMed ID: 30193804
[TBL] [Abstract][Full Text] [Related]
14. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients.
Tetzlaff MT; Nelson KC; Diab A; Staerkel GA; Nagarajan P; Torres-Cabala CA; Chasen BA; Wargo JA; Prieto VG; Amaria RN; Curry JL
J Immunother Cancer; 2018 Feb; 6(1):14. PubMed ID: 29433571
[TBL] [Abstract][Full Text] [Related]
15. Safety of immune checkpoint inhibitors in Chinese patients with melanoma.
Wen X; Wang Y; Ding Y; Li D; Li J; Guo Y; Peng R; Zhao J; Zhang X; Zhang XS
Melanoma Res; 2016 Jun; 26(3):284-9. PubMed ID: 27116334
[TBL] [Abstract][Full Text] [Related]
16. Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus-like to Grover-like lesions.
Chen WS; Tetzlaff MT; Diwan H; Jahan-Tigh R; Diab A; Nelson K; Glitza IC; Kaunitz GJ; Johnson D; Torres-Cabala C; Pacha O; Taube JM; Maloney K; Prieto VG; Curry JL
J Cutan Pathol; 2018 Oct; 45(10):764-773. PubMed ID: 29943453
[TBL] [Abstract][Full Text] [Related]
17. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
Sibaud V; Meyer N; Lamant L; Vigarios E; Mazieres J; Delord JP
Curr Opin Oncol; 2016 Jul; 28(4):254-63. PubMed ID: 27136138
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
19. A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
Levine O; Devji T; Xie F
Hum Vaccin Immunother; 2017 Aug; 13(8):1765-1767. PubMed ID: 28481695
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
Diem S; Keller F; Rüesch R; Maillard SA; Speiser DE; Dummer R; Siano M; Urner-Bloch U; Goldinger SM; Flatz L
J Immunother; 2016; 39(9):379-382. PubMed ID: 27662340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
